Better Health. Better Life.

Title Created Date
M Pharmaceutical Inc. Seeks To Expand Weight Management & Women’s Health Treatment Portfolio Through Additional Innovative Technologies 22 December 2016
M Pharmaceutical Inc. Previews Business Strategy For Developing And Commercializing Prescription Strength C-103, Reformulated Orlistat 29 November 2016
M Pharmaceutical Inc. To Attend The 2016 Meeting Of The American Association Of Pharmaceutical Scientist (AAPS) 10 November 2016
M Pharmaceutical Inc. Closes Acquisition Of FDA Cleared Innovative Infertility Treatment - A Natural Conception Lubricant 08 November 2016
M Pharmaceutical Inc. Shareholder Update Letter Highlights Acquisitions, Financing, Product Development & Study Results 27 October 2016
M Pharmaceutical Inc. Announces United States Patent And Trademark Office Update For Their “Dual Compartment Capsule For The Administration Of Orlistat" 13 October 2016
M Pharmaceutical Inc. Engages Camargo Pharmaceutical Services To Develop Regulatory Strategy For Newly Acquired Chelatexx Technology 11 October 2016
M Pharmaceutical Inc. To Acquire FDA Approved, Innovative Infertility Treatment Through Acquisition Of Toconceive Llc. - A Natural Conception Lubricant 06 October 2016
M Pharmaceutical Announces Final Closing Of Private Placement 20 September 2016
M Pharmaceutical Inc. Announces Successful Findings From Third Of Three Pilot Studies Validating Its Proprietary Reformulation Of Orlistat, C-103 – Consistently, The Three Studies Were Effective In Eliminating A Minimum Of 97% Of Orlistat’s G.I. Adverse E 15 September 2016
M Pharmaceutical Inc. Enters Into Exclusive Negotiations To Acquire Private Pharmaceutical Company With An Fda Approved Women’s Health Product 12 September 2016
M Pharmaceutical Announces First Closing of Private Placement 07 September 2016
M Pharmaceutical Inc. Announces Successful Findings From Second Of Three Pilot Studies Validating Its Proprietary Reformulation Of Orlistat, C-103 Eliminates 98% Of Orlistat’s Gastrointestinal Adverse Effects 29 August 2016
M Pharmaceutical Announces Private Placement 25 August 2016
M Pharmaceutical Inc. Announces The Successful Design And Engineering Of Their Unique "Sequential Release Dual Compartment Gelatin Capsule" Required For The Effective Delivery Of C-103, Re-Formulated Orlistat 16 August 2016
M Pharmaceutical Inc. Announces Findings From Previous Lead Pilot Study Showing C-103, A Proprietary Reformulation Of Orlistat, Eliminates 98% Of Orlistat’s Gastrointestinal Adverse Effects 11 August 2016
M Pharmaceutical Update On Chelatexx, LLC Acquisition 09 August 2016
M Pharmaceutical Inc. Appoints President Of U.S. Operating Company Based In Greater Cincinnati 02 August 2016
M Pharmaceutical Inc. Announces New U.S. Operating Company Located In Greater Cincinnati 29 July 2016
M Pharmaceutical Closes On Chelatexx, Llc Acquisition 15 July 2016
M Pharmaceutical Provides Update On Chelatexx, Llc Acqusition 01 June 2016
M Pharmaceutical Announces Brian Keane as Interim President and CEO 04 April 2016
M Pharmaceutical Announces Change to Management 15 March 2016

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.